Compare Fox Corp Class B (FOX) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fox Corp Class B vs Incyte Corporation — how do they compare? Fox Corp Class B trades at $59.02 (market cap $25.36B), while Incyte Corporation trades at $112.8 (market cap $22.85B). The key difference: Fox Corp Class B and Incyte Corporation are close in size by market cap, and Fox Corp Class B pays a 1.02% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals — on Pluang, investors hold Fox Corp Class B for 75 Days and Incyte Corporation for 33 Days on average.
| FOX | INCY | |
|---|---|---|
Market Cap | $25.36B | $22.85B |
Volume | 886,620 | 1,927,029 |
Sector | Media | Health |
52-Week High | $67.76 | $129.93 |
52-Week Low | $44.39 | $83.80 |
Typical Hold Time | 75 Days | 33 Days |
Enterprise Value | $28.72B | $18.35B |
Dividend Yield | 1.02% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FOX trades at $55.98, up 0.72% today, with a bearish technical signal but strong fundamentals. Recent earnings beats in Q4 2025, Q1 2026, and Q2 2026, alongside a net income margin of 13.88% in 2025, highlight robust profitability. The company maintains solid cash flow and a healthy balance sheet with $5.35B in cash. Analyst consensus is a Buy with a $84.75 price target, though technical indicators show resistance near $57.
The stock presents a value opportunity with a P/E of 14.59 and P/S of 1.44, supported by earnings growth. Risks include a projected net cash flow decline to -$1.1B in 2026 and bearish technical trends. Upside potential exists if the company meets Q3 2026 EPS expectations of 2.06, but investors should monitor cash flow trends and competitive pressures in the media sector.
Incyte (INCY) trades at $113.44, up 0.63% with a bullish technical outlook despite mixed moving average signals. The company shows strong fundamentals with $5.14B revenue, 27.71% net margin, and robust cash flow of $1.41B. Recent FDA approval for Atebrioz and pipeline expansion beyond JAKAFI position the company for growth, with analysts projecting $5.8B revenue and $1.6B net income for 2026.
The investment case centers on Incyte's successful diversification strategy and strong profitability metrics, though investors face risks from JAKAFI patent expiration in 2029 and near-term earnings volatility. With 52% analyst buy ratings and a $132.43 consensus price target representing 17% upside, the stock offers growth potential but requires monitoring of pipeline execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Fox Corp Class B
Fox represents the assets not sold to Disney by the predecessor firm, Twenty First Century Fox. The remaining assets include Fox News, the FOX broadcast network, FS1 and FS2, Fox Business, Big Ten Network, 28 owned and operated local television stations of which 17 are affiliated with the Fox Network, and the Fox Studios lot. The Murdoch family continues to control the successor firm, which represents a large-scale bet on the value of live sports and news in the U.S. market.
Read more on FOX →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
